Gangtok Chronicle

Metastatic Triple-Negative Breast Cancer Market Analysis, Market Size, Epidemiology, Leading Companies And Competitive Analysis By DelveInsight

 Breaking News
  • No posts were found

Metastatic Triple-Negative Breast Cancer Market Analysis, Market Size, Epidemiology, Leading Companies And Competitive Analysis By DelveInsight

September 09
13:35 2021
Metastatic Triple-Negative Breast Cancer Market Analysis, Market Size, Epidemiology, Leading Companies And Competitive Analysis By DelveInsight
DelveInsight Business Research LLP
DelveInsight’s “Metastatic triple-negative breast cancer (mTNBC) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Metastatic triple-negative breast cancer (mTNBC), historical and forecasted epidemiology as well as the Metastatic triple-negative breast cancer (mTNBC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on “Metastatic Triple-Negative Breast Cancer – Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s Metastatic Triple-Negative Breast Cancer – Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the Metastatic Triple-Negative Breast Cancer, historical and forecasted epidemiology as well as the Metastatic Triple-Negative Breast Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Report:

  • DelveInsight has also estimated the Subtype specific cases of TNBC, which are  ER-, PR- and HER2-. In the United States, there were 4,793 cases of HER2-TNBC, followed by PR- and ER- subtypes.

  • Out of the total cases of Triple-Negative Breast Cancer, 8,466 cases were in the advanced stage in the US in 2017. 

  • Amongst the EU-5 countries (Germany, France, the United Kingdom, Spain, and Italy), Germany had the highest diagnosed incidence of TNBC and accounted for 12,516 cases followed by France and Italy in the year 2017.

Key benefits of the report:

  1. Metastatic Triple-Negative Breast Cancer  market report covers a descriptive overview and comprehensive insight of the Metastatic Triple-Negative Breast Cancer  epidemiology and Metastatic Triple-Negative Breast Cancer  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

  2. The Metastatic Triple-Negative Breast Cancer market report provides insights on the current and emerging therapies.

  3. Metastatic Triple-Negative Breast Cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.

  4. The Metastatic Triple-Negative Breast Cancer market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Metastatic Triple-Negative Breast Cancer market.

Got queries? Click here to know more about Metastatic Triple-Negative Breast Cancer Market Landscape.

Metastatic Triple-Negative Breast Cancer Overview

Metastatic Triple-Negative Breast Cancer (mTNBC) is defined as the metastatic tumor where the estrogen and progesterone (ER/PR)  are negative, as assessed by immunohistochemistry (IHC), and there is a lack of overexpression of HER2, as assessed by immunohistochemistry (IHC), or the absence of its gene amplification, as assessed by fluorescence in situ hybridization technique. The epidemiological risk factor profiles also vary between TNBC (ER-PR-HER2-) and other breast cancers. 

The key players involved in the Metastatic Triple-Negative Breast Cancer  market:

  • HiberCell

  • Hoffmann-La Roche

  • Infinity Pharmaceuticals

  • CytoDyn

  • Treadwell Therapeutics 

  • And others

The launch of the emerging therapies is expected to significantly impact the Metastatic Triple-Negative Breast Cancer treatment scenario in the upcoming years:-

Drug covered

  • Imprime PGG

  • Ipatasertib

  • IPI-549 (Eganelisib)

  • Leronlimab (PRO 140)

  • Leronlimab (PRO 140)

  • CFI-400945

  • And others.

Request a free sample report @ Metastatic Triple-Negative Breast Cancer Market Outlook

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Metastatic Triple-Negative Breast Cancer Patient Share (%) Overview at a Glance

5. Metastatic Triple-Negative Breast Cancer Market Overview at a Glance

6. Metastatic Triple-Negative Breast Cancer Disease Background and Overview

7. Metastatic Triple-Negative Breast Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Metastatic Triple-Negative Breast Cancer 

9. Metastatic Triple-Negative Breast Cancer Current Treatment and Medical Practices

10. Unmet Needs

11. Metastatic Triple-Negative Breast Cancer Emerging Therapies

12. Metastatic Triple-Negative Breast Cancer  Market Outlook

13. Country-Wise Metastatic Triple-Negative Breast Cancer Market Analysis (2017–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Metastatic Triple-Negative Breast Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/ghaziabadonline/gangtokchronicle.in/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share

Categories